Point-of-care molecular vaginitis testing improves likelihood of appropriate treatment

Women with vaginitis symptoms were significantly more likely to receive appropriate treatment within 24 hours when tested with a multiplex molecular point-of-care test compared with standard diagnostic methods, according to results from the first randomized clinical trial (NCT06438575) evaluating this approach, published in Sexually Transmitted Diseases.^1,2

The study, led by investigators at Magee-Womens Research Institute and the University of Pittsburgh and supported by an investigator-initiated grant from Cepheid, evaluated the Xpert Xpress MVP (multiplex vaginal panel), a CLIA-waived nucleic acid amplification test (NAAT) that detects bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis (TV) from a single self-collected vaginal sample.^1,2 Standard diagnostic methods used in the usual care arm included symptom-based assessment, pH testing, odor evaluation, and wet mount microscopy.¹

A total of 276 women seeking care for vaginal symptoms, including discharge, odor, itch, irritation, burning, or pain, were enrolled between July 2024 and February 2025 and randomized 1:1 to immediate point-of-care NAAT results or usual care.² The median participant age was 33 years (range 17 to 76), with a self-reported racial distribution of 50% Black, 41% White, and 9% other; 7% of participants were pregnant.² The prevalence of BV, candidiasis, and TV in the study population was 44.7%, 32%, and 5.1%, respectively, and 36.9% of women had no detectable pathogens.²

True positives were defined as samples testing positive for BV, candidiasis, or TV by 2 FDA-cleared NAATs.² The investigators reported that 25% of providers in the usual care arm relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections approximately 50% to 63% of the time.¹

Did use of Xpert Xpress MVP lead to care?

Among women tested with Xpert Xpress MVP, 89.6% received appropriate treatment within 24 hours of their clinic visit compared with 51.9% in the usual care arm (P < 0.001).^1,2 Appropriate treatment rates were significantly higher with point-of-care NAAT versus usual care for BV, candidiasis, and no infection.²

Overtreatment in the absence of detectable pathogens was a notable finding. Among women confirmed to have no vaginal infection, 50% in the usual care arm received unnecessary antimicrobial treatment compared with 27.1% in the Xpert Xpress MVP arm (P = 0.031).¹

"Overuse of antimicrobials when no pathogens are detected should be avoided since it can contribute to antimicrobial resistance, may disrupt the vaginal microbiome, may cause side effects and adds costs to women and their insurers," the study authors noted.

Provider satisfaction and clinical context

Among healthcare providers whose patients were randomized to the Xpert Xpress MVP arm, 87% indicated they would like to incorporate this type of testing into routine clinical practice, and the majority reported positive perceptions of the test's turnaround time and workflow.¹

"Women presenting with vaginal symptoms deserve accurate answers and timely, evidence-based care," said Connie Savor, MD, Chief Medical Officer at Cepheid. "This study demonstrates how molecular point-of-care tests… can help clinicians make more informed treatment decisions in a single visit, improving care while reducing unnecessary treatment."¹

References

1. Cepheid. Cepheid announces publication of study demonstrating real-world impact of Xpert Xpress MVP point-of-care test for vaginitis. Press release. Published 2026. Accessed July 7, 2026.
2. Hillier SL, Macio I, Gallagher R, Meyn L, Beamer M, Zamborsky T, Campbell T, Bunge K, Wiesenfeld HC. Randomized study of usual care vs Xpert Xpress MVP at the point of care for accurate diagnosis and appropriate treatment of vaginal infections. Sex Transm Dis. 2026 May 12. doi:10.1097/OLQ.0000000000002343